Diadem Biotherapeutics

Diadem Biotherapeutics

Biotherapeutics company focused on medicines for chronic inflammation, metabolic disease and autoimmune disease

Diadem Biotherapeutics is based in Los Angeles, CA. The company's founders were located at the IndieBio accelerator in San Francisco through January 2020. Diadem Biotherapeutics develops shelf-stable, engineered exosomes for the anti-inflammatory market, including the disease Chronic obstructive pulmonary disease (COPD). The company is also developing medicines for metabolic and autoimmune diseases. Diadem is focused on biotherapeutic materials produces through biological methods such as recombinant DNA technology. Diadem Biotherapeutics is engineering inhalable exosomes that act as immune modulators.

The company is developing a SARS-CoV-2 (COVID-19) vaccine using engineering exosomes as the antigen. The exosome will be engineered to have surface bound SARS-CoV-2 proteins and immune-stimulating ligands, so that they are similar to non-replicative virus-like particles. Immune stimulating ligands such as 4-1BB may be engineered onto the exosomes as well to increase immune response and memory for the SARS-CoV-2 antigen.

Timeline

Funding rounds

Funding round
Funding type
Funding round amount (USD)
Funding round date
Investment
Diadem Biotherapeutics Seed round, August 2019
August 12, 2019
1 Result
Results per page:
Page 1 of 1

People

Name
Role
LinkedIn

Mickey Pentecost

Co-Founder, CEO, Board Member

Wojciech Bartkowski

Co-Founder, CTO, Board Member

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.